Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
#3081 An Atypical Presentation of a Neuroendocrine Carcinoma of Unknown Origin
Introduction: Neuroendocrine carcinomas (NEC) of unknown primary site are uncommon. Most arise from an occult/clinically undetectable primary. Primary NEC of genitourinary tract are rare. High-grade (HG) carcinoms, are rapidly growing and aggressive but usually responsive to platinum-based combination chemotherapy.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Da Silva Dias D, Gosálbez B,
Keywords: .,
Introduction: G3NEC are heterogeneous and aggressive diseases which can arise in different organs. Platinum-etoposide combination is used as first line treatment whatever the primary. Rb has been suggested to be a predictive/prognostic factor.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Hadoux J
Authors: Hadoux J, Kanaan C, Planchard D, Malka D, Ducreux M,
Keywords: Neuroendocrine carcinoma, Platinum-etoposide, Rb,
Introduction: Well-differentiated neuroendocrine tumors G3 (NETsG3) pts have a different biological behavior compared to those with neuroendocrine carcinomas (NECs). Sensitivity to platinum depends on Ki67 and there is no standard second line (2L). Neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) are predictive factors of cancer survival, but with limited evidence in NENs.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Cameselle-Garcia S, Sardo E, Landolfi S, Merino-Casabiel X, Sánchez J,
Keywords: Neuroendocrine Neoplasms, Inflammatory Biomarkers, Gastroenteropancreatic,
Introduction: Metastatic WHO grade 3 extra-pulmonary neuroendocrine carcinomas (EP-NEC) have a poor prognosis and optimal treatment after first-line platinum-etoposide chemotherapy remains unclear. A recent, small phase II study combining ipilimumab and nivolumab showed promising results
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Vandamme T, De Backer L, Van den Brande J, Op de Beeck B, Driessen A,
Keywords: NEC, immunotherapy,
Introduction: Etoposide-platinum (EP) chemotherapy has long stood as the reference treatment of grade 3 neuroendocrine neoplasms (G3 NEN). However, G3 NEN are heterogeneous, including well differentiated tumours (NET) and poorly differentiated carcinomas of large (LCNEC) or small (SCNEC) cell type, whose identification can be challenging and response to EP be very variable, usually low in NET.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Lacombe C, De Rycke O, Chen R, Colnot N, Hentic O,
Keywords: grade 3, chemotherapy, biomarkers, etoposide-platinum, pRb, p53,